Lyumjev Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of diabetes globally, rising demand for rapid-acting insulin formulations, expansion of outpatient diabetes treatment, improved insulin delivery technologies, wider physician adoption of insulin analogs.

The growth in the forecast period can be attributed to increasing adoption of personalized diabetes therapies, growing integration with digital glucose monitoring systems, rising demand for flexible insulin dosing options, expansion of home-based diabetes care, increasing focus on improved patient adherence. Major trends in the forecast period include increasing adoption of ultra-rapid acting insulin therapies, rising preference for postprandial glucose control solutions, growing use of pre-filled insulin delivery devices, expansion of patient-centric diabetes management approaches, enhanced focus on faster insulin absorption profiles.

The increasing prevalence of diabetes is expected to drive the growth of the Lyumjev market in the coming years. Diabetes refers to a group of long-term medical conditions that impact how the body regulates blood sugar (glucose). The rise in diabetes prevalence is linked to factors such as unhealthy eating patterns, inactive lifestyles, genetic susceptibility, and a growing aging population. Lyumjev supports diabetes management by regulating blood sugar levels through fast-acting insulin, rapidly reducing post-meal glucose spikes. For instance, in February 2024, according to Diabetes Canada, a Canada-based national charity, the number of people diagnosed with diabetes (type 1 and type 2) reached 4,006,850 in 2024 and is projected to rise to 5,300,670 by 2034. Therefore, the growing prevalence of diabetes fuels the Lyumjev market.

The increasing prevalence of sedentary lifestyles is expected to substantially propel the growth of the Lyumjev market in the coming years. Sedentary lifestyles describe everyday routines or behaviors characterized by very low levels of physical activity, with individuals spending much of their time sitting or reclining. The rise in sedentary lifestyles is driven by greater dependence on technology, desk-based occupations, extended screen exposure, and the ease of modern transportation, all of which limit physical movement and promote prolonged sitting. Lyumjev is formulated to work more quickly than conventional rapid-acting insulins, starting to reduce blood glucose levels within minutes after administration. It benefits sedentary individuals, who often experience more significant post-meal blood sugar elevations due to reduced physical activity. For instance, in June 2024, according to the World Health Organization (WHO), a Switzerland-based international public health organization, data indicated that nearly one-third (31%) of adults globally - around 1.8 billion people - did not achieve the recommended levels of physical activity in 2022, and inactivity rates are projected to increase further to 35% by 2030. Therefore, the growing prevalence of sedentary lifestyles is driving the Lyumjev market.

The increasing healthcare expenditure is anticipated to support the growth of the Lyumjev market in the coming years. Healthcare expenditure represents the total monetary resources allocated by individuals, organizations, and governments toward the prevention, treatment, and management of health conditions. Healthcare spending is rising due to advancements in medical technology, as the introduction of new diagnostic methods, therapies, and innovative treatments often involves higher costs, contributing to increased overall healthcare expenses. Growing healthcare expenditure is enabling wider access to advanced diabetes treatments, creating favorable conditions for Lyumjev to expand its patient base and accelerate adoption. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency that oversees the Medicare and Medicaid programs, U.S. healthcare expenditures grew by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Therefore, rising healthcare expenditure is contributing to the growth of the Lyumjev market.

Major companies operating in the lyumjev market are Eli Lilly and Company.

North America was the largest region in the lyumjev market in 2025. The regions covered in the lyumjev market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lyumjev market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the lyumjev market by increasing costs of imported active pharmaceutical ingredients, specialized excipients, sterile packaging materials, and injection device components used in insulin manufacturing. North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces pricing pressure on bulk insulin production and export activities. These tariffs are contributing to higher production costs and pricing pressure across hospital and retail pharmacy channels. However, they are also encouraging localized API manufacturing, regional fill-and-finish investments, and greater supply chain resilience for rapid-acting insulin products.

The lyumjev market research report is one of a series of new reports that provides lyumjev market statistics, including lyumjev industry global market size, regional shares, competitors with a lyumjev market share, detailed lyumjev market segments, market trends and opportunities, and any further data you may need to thrive in the lyumjev industry. This lyumjev market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lyumjev is a fast-acting insulin formulation used to control blood glucose levels in individuals with diabetes. Its mechanism of action involves the quick absorption of insulin lispro, which helps manage blood sugar by promoting glucose uptake into cells, suppressing glucose production by the liver, and more effectively regulating post-meal blood sugar spikes.

The primary indication types of Lyumjev include the treatment of type 1 diabetes, the treatment of type 2 diabetes, and the management of postprandial hyperglycemia. The use of Lyumjev for treating type 1 diabetes involves administering insulin to regulate blood glucose levels by substituting the insulin that the body is unable to produce. It is offered in multiple forms, such as injectable formulations (solutions for injection) and pre-filled pens (Lyumjev KwikPen). It is prescribed across different population groups, including pediatric, adult, and geriatric patients. The product is distributed through several channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Additionally, it is utilized by various end users, such as hospitals, diabetes clinics, specialty pharmacies, and home healthcare providers.

The lyumjev market consists of sales of products including lyumjev U-100, lyumjev U-200, and lyumjev for insulin pumps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.